by Mark Curtis | Dec 23, 2014
. Welcome to your Update from the Clinic for the month of November. NeoStem announced initial positive data from its Phase 2 study in acute myocardial infarction. Neuralstem’s human neural stem cells are shown to have long-term viability following transplant, while...
by James Smith | Dec 18, 2014
. With contributions from David Brindley Manufacturing may not be the first thing that springs to mind when regenerative medicine is mentioned. Most will think of the enormous potential for cell therapies or transplantation or editing of faulty genes. However, having...
by James Smith | Dec 11, 2014
. With contributions from David Brindley. We recently discussed the role that consortia could play in accelerating the timeline of discovering and implementing new treatments, covering the ‘partnering’ aspect of the ‘Partnering for Cures’ conference held in New York...
by Mark Curtis | Dec 4, 2014
. The Edmonton Protocol for the transplantation of insulin producing cells into individuals with type 1 diabetes (T1DM) has a cost per quality-adjusted life year (QALY) of ~$165,000. This is more than three times the willingness-to-pay (WTP) in Canada, and comfortably...
by Mark Curtis | Nov 27, 2014
. Welcome to your Update from the Clinic for the month of October. Northwest Biotherapeutics continues to receive support for its cancer vaccine platform in Europe. Neuralstem and StemCells provided updates on their respective clinical programs for spinal cord injury....
Comments